Literature DB >> 23904462

Risk assessment of esophageal adenocarcinoma using γ-H2AX assay.

Enping Xu1, Yilei Gong, Jian Gu, Lin Jie, Jaffer A Ajani, Xifeng Wu.   

Abstract

BACKGROUND: Mutagen-induced DNA damage as measured in peripheral blood lymphocytes (PBL) has been associated with increased risks of cancers. The formation of γ-H2AX is an early cellular response to DNA double-strand breaks (DSB). We hypothesize that higher level of radiation-induced γ-H2AX in PBLs may be associated with an increased risk of esophageal adenocarcinoma.
METHODS: Laser scanning cytometer-based immunocytochemical method was used to measure baseline and irradiation-induced γ-H2AX levels in PBLs from 211 patients with esophageal adenocarcinoma and 211 healthy controls. The ratio of induced γ-H2AX level to baseline level was used to evaluate individual susceptibility to DSBs. Relative risks for esophageal adenocarcinoma associated with γ-H2AX were assessed by multivariable logistic regression analysis.
RESULTS: Radiation-induced γ-H2AX level and the γ-H2AX ratio were significantly higher in cases than in controls. Dichotomized at the median in controls, a significantly increased risk for esophageal adenocarcinoma was observed in association with high γ-H2AX ratio [OR = 2.94; 95% confidence interval (CI), 1.83-4.72]. Quartile analyses showed significant dose-response associations between higher γ-H2AX ratio and increased risk of esophageal adenocarcinoma (Ptrend, 1.64E-06). In addition, joint effect between γ-H2AX ratio and smoking was observed: smokers who had high γ-H2AX ratio exhibited the highest risk of esophageal adenocarcinoma (OR = 5.53; 95% CI, 2.71-11.25) compared with never smokers with low γ-H2AX ratio.
CONCLUSION: Radiation-induced DNA damage assessed by γ-H2AX ratio is associated with an increased risk of esophageal adenocarcinoma. IMPACT: γ-H2AX assay is a new and robust method to measure DSB damage in PBLs, which can be used to assess mutagen sensitivity and esophageal adenocarcinoma risk.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23904462      PMCID: PMC3824382          DOI: 10.1158/1055-9965.EPI-13-0485

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  36 in total

1.  Frequent chromosomal translocations induced by DNA double-strand breaks.

Authors:  C Richardson; M Jasin
Journal:  Nature       Date:  2000-06-08       Impact factor: 49.962

2.  Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west.

Authors:  Janusz A Jankowski; Dawn Provenzale; Paul Moayyedi
Journal:  Gastroenterology       Date:  2002-02       Impact factor: 22.682

Review 3.  Mutagen sensitivity: a biological marker of cancer susceptibility.

Authors:  T C Hsu; M R Spitz; S P Schantz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1991 Nov-Dec       Impact factor: 4.254

4.  Mutagen sensitivity has high heritability: evidence from a twin study.

Authors:  Xifeng Wu; Margaret R Spitz; Christopher I Amos; Jie Lin; Lina Shao; Jian Gu; Mariza de Andrade; Neal L Benowitz; Peter G Shields; Gary E Swan
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

5.  Quantitative detection of (125)IdU-induced DNA double-strand breaks with gamma-H2AX antibody.

Authors:  Olga A Sedelnikova; Emmy P Rogakou; Igor G Panyutin; William M Bonner
Journal:  Radiat Res       Date:  2002-10       Impact factor: 2.841

6.  Alkaline single-cell gel electrophoresis (comet assay): a simple technique to show genomic instability in sporadic breast cancer.

Authors:  S Colleu-Durel; N Guitton; K Nourgalieva; F Legue; J Lévêque; B Danic; C Chenal
Journal:  Eur J Cancer       Date:  2004-02       Impact factor: 9.162

Review 7.  Reflux, Barrett's oesophagus and adenocarcinoma: burning questions.

Authors:  Christopher P Wild; Laura J Hardie
Journal:  Nat Rev Cancer       Date:  2003-09       Impact factor: 60.716

Review 8.  DNA repair pathways as targets for cancer therapy.

Authors:  Thomas Helleday; Eva Petermann; Cecilia Lundin; Ben Hodgson; Ricky A Sharma
Journal:  Nat Rev Cancer       Date:  2008-03       Impact factor: 60.716

9.  H2AX phosphorylation at the sites of DNA double-strand breaks in cultivated mammalian cells and tissues.

Authors:  Denis V Firsanov; Liudmila V Solovjeva; Maria P Svetlova
Journal:  Clin Epigenetics       Date:  2011-06-25       Impact factor: 6.551

10.  Residual gammaH2AX foci as an indication of lethal DNA lesions.

Authors:  Judit P Banáth; Dmitry Klokov; Susan H MacPhail; C Adriana Banuelos; Peggy L Olive
Journal:  BMC Cancer       Date:  2010-01-05       Impact factor: 4.430

View more
  6 in total

1.  CT Scanning: Is the Contrast Material Enhancing the Radiation Dose and Cancer Risk as Well as the Image?

Authors:  Amy Berrington de Gonzalez; Ruth A Kleinerman
Journal:  Radiology       Date:  2015-06       Impact factor: 11.105

2.  Reduced DNA double-strand break repair capacity and risk of squamous cell carcinoma of the head and neck--A case-control study.

Authors:  Zhensheng Liu; Hongliang Liu; Fengqin Gao; Kristina R Dahlstrom; Erich M Sturgis; Qingyi Wei
Journal:  DNA Repair (Amst)       Date:  2016-03-02

3.  Epstein-Barr virus BALF3 mediates genomic instability and progressive malignancy in nasopharyngeal carcinoma.

Authors:  Shih-Hsin Chiu; Chung-Chun Wu; Chih-Yeu Fang; Shu-Ling Yu; Hui-Yu Hsu; Yen-Hung Chow; Jen-Yang Chen
Journal:  Oncotarget       Date:  2014-09-30

4.  Short-term markers of DNA damage among roofers who work with hot asphalt.

Authors:  Berrin Serdar; Stephen Brindley; Greg Dooley; John Volckens; Elizabeth Juarez-Colunga; Ryan Gan
Journal:  Environ Health       Date:  2016-10-20       Impact factor: 5.984

Review 5.  Low-dose or low-dose-rate ionizing radiation-induced bioeffects in animal models.

Authors:  Feng Ru Tang; Weng Keong Loke; Boo Cheong Khoo
Journal:  J Radiat Res       Date:  2017-03-01       Impact factor: 2.724

6.  Selective synergistic anticancer effects of cisplatin and oridonin against human p53-mutant esophageal squamous carcinoma cells.

Authors:  Huiyu Yang; Jie Wang; Suliman Khan; Yuanying Zhang; Kuicheng Zhu; Enhui Zhou; Meiyuan Gong; Bingrong Liu; Quancheng Kan; Qi Zhang
Journal:  Anticancer Drugs       Date:  2022-01-01       Impact factor: 2.248

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.